Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

What is the optimal timing of radiotherapy and immunotherapy in lung cancer? A meta-analysis of randomized trials using reconstructed Kaplan–Meier data.

Ahmed Sayed Abdelmaksoud Osman, Mostafa Adel T. Mahmoud, Mark Messak et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20076

e20076 Background: The increasing use of combined radiotherapy (RT) and immunotherapy (IO) in lung cancer is driven by evi...

ILF2 as a predictor of cisplatin resistance and clinical outcomes in intrahepatic cholangiocarcinoma.

Kodai Abe, Kelly Chong, Yuta Abe et al. Jun 01, 2026 pp. 3122-3122 10.1200/jco.2026.44.16_suppl.3122

3122 Background: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive biliary tract cancer with increasing global...

Cigarette smoking on outcomes with osimertinib in <i>EGFR</i> -mutated non–small cell lung cancer: A real-world analysis.

Mohammad Alamgir, Muhammad Yousaf, Jennifer Collins et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20680

e20680 Background: Osimertinib is a preferred therapy for patients with EGFR-mutated non–small cell lung cancer (NSCLC). H...

Locally advanced or metastatic thyroid cancer treated with donafenib with or without chemotherapy: A real-world study.

Nan Feng, Xucai Zheng Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18019

e18019 Background: Neoadjuvant therapy is often required for patients (pts) with locally advanced thyroid cancer (LATC). O...

SCIntMatch: A probabilistic soft-matching framework for integrating single-cell genomes and transcriptomes to dissect adaptive resistance in patients with esophageal cancer.

Yue Lyu, Rui Ye, Sadhna Aggarwal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16012

e16012 Background: Adaptive resistance remains a major barrier to effective radiation therapy in esophageal cancer. While...

Early detection of second primary solid tumors in patients with an index solid malignancy.

Ernesto Gil Deza, Carlos Fernando Garcia Gerardi, Tatiana Perez Carmona et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13792

e13792 Background: Multiple primary malignant neoplasms (MPMN) are defined as two or more independent malignant tumors wit...

Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.

Stephane Champiat, Luke Kuttschreuter, Neal Shiv Chawla et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2681

TPS2681 Background: The immunosuppressive pathway of prostaglandin E 2 (PGE...

Evaluation of clinicopathological features and prognosis of patients with small cell carcinoma of gastrointestinal system origin.

Izzet Dogan, Mustafa Bozkurt, Ertugrul Tekce et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16481

e16481 Background: Small cell carcinoma of gastrointestinal origin is a rare, highly aggressive neuroendocrine malignancy...

Conditioning intensity and post-transplant outcomes in acute myeloid leukemia: A real-world analysis.

Astha Koolwal Kapoor, Yanal Mufeed Alnimer, Nicole Lisek et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18573

e18573 Background: The choice of conditioning intensity for patients with acute myeloid leukemia (AML) undergoing allogene...

Expression of FGFR2b and HER2 in gastric cancer: Implications for targeted therapy selection.

Fei Chu, Aaron Hong, Jiaxing Zhao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16106

e16106 Background: FGFR2b and HER2 are clinically relevant therapeutic targets in gastric cancer (GC), with multiple targe...

Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.

Xin Gao, Rafael Morales-Barrera, Tian Zhang et al. Jun 01, 2026 pp. 4517-4517 10.1200/jco.2026.44.16_suppl.4517

4517 Background: Enfortumab vedotin plus pembrolizumab (EVP) is the current first-line standard of care for locally advanc...

Real-world effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Preliminary results from the prospective, non-interventional MagnetisMM-16 study.

Jindriska Lindsay, Werner Freier, John Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19507

e19507 Background: Elranatamab is a B-cell maturation antigen–CD3 bispecific antibody approved for the treatment of adult...

Cumulative low-dose ionizing radiation exposure in frequent emergency department encounters and implications of carcinogenic risk.

Rida Haqqani, Nicholas Basile, Jonathan Riddle et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23157

e23157 Background: Repeated low-dose ionizing radiation (IR) over short intervals can accumulate causing DNA damage and in...

Nutraceutical therapies for radiation-induced injury: A systematic review and meta-analysis.

Saikrishna Vallamchetla, Neisy Vazquez, Yazmin Odia Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24196

e24196 Background: Radiation-induced edema and necrosis are common, dose-limiting toxicities. Corticosteroids remain first...

A patient-tailored protein marker blood test for monitoring treatment response and postoperative recurrence across multiple cancers.

Mao Mao, Wenjian Wang, Qingqi Ren et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15047

e15047 Background: ctDNA-based minimal residual disease (MRD) assays are increasingly used for post-treatment surveillance...

Racial and ethnic differences in breast-conserving surgery after neoadjuvant chemotherapy for HER2-positive and triple-negative breast cancer.

Alanna J. Hickey, Fangbai Sun, Fangyong Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13724

e13724 Background: Neoadjuvant chemotherapy (NACT) increases eligibility for breast-conserving surgery (BCS) among patient...

Siltuximab for the prevention of severe immune-related adverse events during immune checkpoint inhibitor rechallenge in advanced cancer: First interim analysis of the CIRES trial.

Mingjia Li, Amir Mortazavi, Floor Jenniskens Backes et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24146

e24146 Background: Immune checkpoint inhibitors (ICI) predisposes patients to unpredictable irAEs. Many patients who had i...

Initial findings from the PROMISE Registry, a US decentralized, prospective prostate cancer genetic registry.

Heather H. Cheng, Justin Lorentz, Andrew J. Armstrong et al. Jun 01, 2026 pp. 10610-10610 10.1200/jco.2026.44.16_suppl.10610

10610 Background: The role for genetic testing (GT) for prostate cancer (PCa) patients (pts) has expanded to find pts with...

Molecular testing, first-line treatment patterns, and survival in metastatic non–small cell lung cancer in Colombia: The RECAPC multicenter registry.

Ricardo Elias Bruges, Pedro Luis Ramos, Milton Alberto Lombana Quinonez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20670

e20670 Background: Real-world Latin American NSCLC cohorts that jointly capture molecular testing, insurance coverage, tre...

Patient and caregiver knowledge and understanding of acute myeloid leukemia and satisfaction with oncologist communication.

Austin Wesevich, Yingzhu Chen, Soroush Mortaz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24104

e24104 Background: Acute myeloid leukemia (AML) is primarily diagnosed in older adults who often need caregiver support. T...

Association of response with survival in patients with relapsed/refractory high-risk neuroblastoma: A report from NANT Consortium.

Michael Migotsky, Judith Villablanca, Yueh-Yun Chi et al. Jun 01, 2026 pp. 10033-10033 10.1200/jco.2026.44.16_suppl.10033

10033 Background: Patients with relapsed/refractory (RR) high-risk neuroblastoma (HR-NB) have poor survival. Tumor respons...

Comparative analysis of mitochondrial free radical markers in endometrioid adenocarcinoma and an experimental model.

Irina V. Kaplieva, Elena M. Frantsiyants, Irina Valerevna Neskubina et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17627

e17627 Background: Endometrial cancer (EC) is the sixth most common cancer worldwide. In postmenopausal women, adipose tis...

CXCL12 <sup>+</sup> pericytes as drivers of lymphatic dissemination in pancreatic cancer: Integrated single-cell and spatial analysis.

Xiangxu Wang, Yunpeng Liu, Hong-mei Zhang Jun 01, 2026 pp. 4126-4126 10.1200/jco.2026.44.16_suppl.4126

4126 Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits poor prognosis largely due to early lymph node metastasi...

Enrichment of the germline <i> NLRC5 <sup>Pro191Leu</sup> </i> variant in patients with immune checkpoint inhibitor–induced hepatitis.

Shira Gabizon Peretz, Noam Savion Gaiger, Jacqueline Mann et al. Jun 01, 2026 pp. 2660-2660 10.1200/jco.2026.44.16_suppl.2660

2660 Background: Immune checkpoint inhibitor–induced hepatitis (ICI-hepatitis) is a clinically significant immune-related...

A retrospective analysis of concomitant opioid usage with immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma.

Mona Yuan, Christina Boatwright, Alexander Nicholas Sisto et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18103

e18103 Background: Cancer-related pain is a significant consequence of disease for recurrent/metastatic head and neck squa...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page